Premium
Poly(2‐oxazoline)s as Polymer Therapeutics
Author(s) -
Luxenhofer Robert,
Han Yingchao,
Schulz Anita,
Tong Jing,
He Zhijian,
Kabanov Alexander V.,
Jordan Rainer
Publication year - 2012
Publication title -
macromolecular rapid communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.348
H-Index - 154
eISSN - 1521-3927
pISSN - 1022-1336
DOI - 10.1002/marc.201200354
Subject(s) - oxazoline , polymer , nanotechnology , drug delivery , chemistry , materials science , combinatorial chemistry , organic chemistry , catalysis
Poly(2‐oxazoline)s (POx) are currently discussed as an upcoming polymer platform for biomaterials design and especially for polymer therapeutics. POx meet specific requirements needed for the development of next‐generation polymer therapeutics such as biocompatibility, high modulation of solubility, variation of size, architecture as well as chemical functionality. Although in the early 1990s first and promising POx‐based systems were presented, the field lay dormant for almost two decades. Only very recently, POx‐based polymer therapeutics came back into the focus of very intensive research. In this review, we give an overview on the chemistry and physicochemical properties of POx and summarize the research of POx–protein conjugates, POx–drug conjugates, POx‐based polyplexes and POx micelles for drug delivery.